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Efficacy of mass drug administration with ivermectin for 
control of scabies and impetigo, with coadministration of 
azithromycin: a single-arm community intervention trial 
Lucia Romani, Michael Marks, Oliver Sokana, Titus Nasi, Bakaai Kamoriki, Billie Cordell, Handan Wand, Margot J Whitfeld, Daniel Engelman, 
Anthony W Solomon, John M Kaldor, Andrew C Steer
Summary
Background In small community-based trials, mass drug administration of ivermectin has been shown to substantially 
decrease the prevalence of both scabies and secondary impetigo; however, their effect at large scale is untested. 
Additionally, combined mass administration of drugs for two or more neglected diseases has potential practical 
advantages, but efficacy of potential combinations should be confirmed.
Methods The azithromycin ivermectin mass drug administration (AIM) trial was a prospective, single-arm, before-and-
after, community intervention study to assess the efficacy of mass drug administration of ivermectin for scabies and 
impetigo, with coadministration of azithromycin for trachoma. Mass drug administration was offered to the entire 
population of Choiseul Province, Solomon Islands, and of this population we randomly selected two sets of ten sentinel 
villages for monitoring, one at baseline and the other at 12 months. Participants were offered a single dose of 20 mg/kg 
azithromycin, using weight-based bands. Children weighing less than 12·5 kg received azithromycin oral suspension 
(20 mg/kg), and infants younger than 6 months received topical 1% tetracycline ointment. For ivermectin, participants 
were offered two doses of oral ivermectin 200 μg/kg 7–14 days apart using weight-based bands, or 5% permethrin 
cream 7–14 days apart if ivermectin was contraindicated. Our study had the primary outcomes of safety and feasibility 
of large-scale mass coadministration of oral ivermectin and azithromycin, which have been previously reported. We 
report here the prevalence of scabies and impetigo in residents of the ten baseline villages compared with those in the 
ten 12-month villages, as measured by examination of the skin, which was a secondary outcome of the trial. Further 
outcomes were comparison of the number of all-cause outpatient attendances at government clinics in Choiseul 
Province at various timepoints before and after mass drug administration. The trial was registered with the Australian 
and New Zealand Trials Registry (ACTRN12615001199505).
Findings During September, 2015, over 4 weeks, 26 188 people (99·3% of the estimated population of Choiseul 
[n=26 372] as determined at the 2009 census) were treated. At baseline, 1399 (84·2%) of 1662 people living in the first 
ten villages had their skin examined, of whom 261 (18·7%) had scabies and 347 (24·8%) had impetigo. At 12 months 
after mass drug administration, 1261 (77·6%) of 1625 people in the second set of ten villages had their skin examined, 
of whom 29 (2·3%) had scabies (relative reduction 88%, 95% CI 76·5–99·3) and 81 (6·4%) had impetigo (relative 
reduction 74%, 63·4–84·7). In the 3 months after mass drug administration, 10 614 attended outpatient clinics for 
any reason compared with 16 602 in the 3 months before administration (decrease of 36·1%, 95% CI 34·7–37·6), and 
during this period attendance for skin sores, boils, and abscesses decreased by 50·9% (95% CI 48·6–53·1).
Interpretation Ivermectin-based mass drug administration can be scaled to a population of over 25 000 with high 
efficacy and this level of efficacy can be achieved when mass drug administration for scabies is integrated with mass 
drug administration of azithromycin for trachoma. These findings will contribute to development of population-level 
control strategies. Further research is needed to assess durability and scalability of mass drug administration in larger, 
non-island populations, and to assess its effect on the severe bacterial complications of scabies. 
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Trust, and the Wellcome Trust.
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Introduction
Scabies is a parasitic skin disease that affects an estimated 
200 million people worldwide.1 It is endemic in many 
tropical developing countries, especially in rural and 
remote communities where access to treatment is 
lacking and domestic overcrowding is common.2
Scabies causes skin inflammation with itch that is 
frequently severe, and often associated with bacterial 
skin infection caused by Staphylococcus aureus and 
Strepto coccus pyogenes (impetigo).3 This infection can 
in turn lead to severe complications including septi­
caemia and post­streptococcal glomerulonephritis, and 
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inc reasing evid ence supports a causal link to acute 
rheumatic fever and rheumatic heart disease.4 In 
April, 2017, growing awareness of the burden of disease 
due to scabies led WHO to recognise it as a neglected 
tropical disease.5 A key next step is the development and 
implementation of effective population­level control 
strategies.
Standard guidelines for scabies control focus on 
treatment of individuals with symptoms, and their 
household contacts.6 Although this approach can achieve 
a high cure rate for affected individuals, reinfestation 
from untreated family and community members occurs 
rapidly in endemic settings, leaving the overall community 
prevalence unchanged.7
By contrast, the strategy of mass drug administration, 
involving treatment of entire communities, has been 
shown in small community­based trials8,9 to substantially 
decrease the prevalence of both scabies and secondary 
impetigo. Several small, single­arm studies8,10,11 sug­
gested the effectiveness of mass drug administration 
using topical permethrin or oral ivermectin,8 with 
ivermectin widely used in lymphatic filariasis and 
onchocerciasis elimination programmes.11 A report 
from Zanzibar, Tanzania,12 showed a decrease of over 
68% in prescriptions of treatments for scabies after 
five annual rounds of mass drug administration with 
ivermectin and albendazole (given for lymphatic 
filariasis) in a population of over 1 million people. The 
first comparative trial of mass drug administration for 
scabies was the skin health inter vention Fiji trial 
(SHIFT),9 which found that ivermectin­based mass drug 
administration decreased the prevalence of scabies by 
94% 1 year after the intervention, and was superior to 
both mass drug administration of topical permethrin 
and standard care. However, the generalisability of this 
finding was restricted by the study’s location in small, 
isolated populations (the ivermectin mass drug 
administration group had a baseline population of 
716 people) and the authors recognised a need for a 
larger scale evaluation.9
High prevalences of scabies have been reported in the 
Pacific region, including in a population­based survey in 
Western Province, Solomon Islands, where the all­ages 
prevalence of scabies was 19·2% and impetigo was 32·7% 
in 2014.13 Other neglected tropical diseases, including 
trachoma, are also public health problems in the Solomon 
Islands.14 A national programme to eliminate trachoma 
was planned in all ten provinces that comprise the 
Solomon Islands and commenced in 2014, using the 
WHO SAFE (ie, surgery for trichiasis, antibiotics, facial 
cleanliness, and environmental improvement) strategy, 
which in cludes mass drug administration with 
azithromycin.14
We planned to use the azithromycin mass drug 
administration infrastructure to study the codelivery of 
ivermectin­based mass drug administration. In the 
azithromycin ivermectin mass drug administration 
(AIM) trial, we had the primary outcomes of safety and 
feasibility of large­scale mass co­administration of 
ivermectin and azithromycin and we recently reported 
these outcomes,15 in particular the absence of serious 
adverse events, in a study population of over 
25 000 people. The secondary outcome focused on the 
efficacy of the intervention against community 
prevalence of scabies and impetigo, which we report in 
this Article.
Research in context
Evidence before this study
Evidence supports scabies control using mass drug 
administration in small island communities. We searched 
PubMed with no language restrictions for publications 
between Jan 1, 1968, and April 30, 2018, using the terms 
“mass drug administration” and “scabies”. We identified two 
non-controlled studies that found mass drug administration 
using topical permethrin (San Blas Islands, Panama) or oral 
ivermectin (Lau Lagoon, Solomon Islands) was highly 
effective in the control of scabies. The skin health 
intervention Fiji trial (SHIFT), the first comparative trial of 
mass drug administration for scabies, observed a decrease in 
scabies prevalence of 94% in the ivermectin-based mass drug 
administration and 67% in the permethrin mass drug 
administration groups at 12 months after the intervention. 
However, all three of these trials included fewer than 
1000 participants in the study groups. A large-scale trial 
of mass drug administration for endemic scabies has 
been advocated as a global health need, but never 
implemented.
Added value of this study
This study showed that ivermectin-based mass drug 
administration can be scaled to a population of over 
25 000 people and achieve a similar efficacy as in small island 
populations. Moreover, this study showed that mass drug 
administration for the public health control of scabies can be 
integrated with azithromycin mass drug administration for 
trachoma, and additional health benefits were achieved, 
specifically decreases in outpatient attendance for multiple 
communicable disease syndromes.
Implications of all the available evidence
This study supports large-scale implementation of 
ivermectin-based mass drug administration for control of 
scabies in locations where the condition is identified as a public 
health priority. Further research questions include the durability 
in decreasing the prevalence of scabies and impetigo and the 
effect of mass drug administration on the complications of 
scabies and impetigo, cost-effectiveness, dosing regimens, and 
acceptability of the intervention to individuals and communities.
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Methods
Study setting and population
This prospective, single­arm, before­and­after, com­
munity intervention trial was undertaken in Choiseul 
Province of the Solomon Islands. The Solomon Islands is 
an island nation in the south Pacific with an estimated 
population of approximately 580 000 people in 2016,16 
living largely in rural and remote settings,17 and has 
a Human Development Index rank of 156 of 188. 
The province of Choiseul occupies the entirety of one 
large and several smaller islands, with a population of 
26 372 recorded in the 2009 national census.16 Health care 
is provided by 17 nurse aid posts, ten rural health clinics, 
one area health centre, and one hospital located in the 
provincial capital, Taro. Based on a 2013 population­based 
survey that showed a prevalence of active trachoma in 
children aged 1–9 years above the elimination threshold,14 
Choiseul had been scheduled to receive azithromycin 
mass drug administration in 2015 through the national 
eye­health programme. These plans were modified to 
incorporate coadministration of ivermectin­based mass 
drug administration for scabies and impetigo.
We selected ten sentinel villages for a baseline skin 
survey. A full list of settlements on the island with their 
populations estimated by use of the most recent census 
was provided by the Ministry of Health and Medical 
Services. We used simple random sampling to select the 
sentinel settlements, with the only inclusion criterion of 
a population of 100–250 people. On the same basis, 1 year 
after the intervention we randomly selected ten different 
villages for the skin survey. At both timepoints, all 
residents of selected villages were invited to participate in 
the skin survey. Additionally, at 12 months, we randomly 
selected four of the initially selected sentinel villages and 
revisted them to evaluate efficacy in paired sites.
All residents of selected sentinel villages were eligible 
to participate in skin surveys for this study, with no age 
restrictions, and written informed consent was obtained 
from adults and from the parents or guardians of 
children.
The trial was registered with the Australian and New 
Zealand Trials Registry (ACTRN12615001199505) and 
approved by the Solomon Islands National Research 
Ethics Committee (15/33) and the Royal Children’s 
Hospital Human Research Ethics Committee (35148A). 
An independent data safety monitoring committee 
oversaw the trial. Verbal consent was obtained from all 
individuals to participate in the mass drug administration 
programme.
Procedures
Teams were assembled from local health staff and trained 
for both azithromycin­based and ivermectin­based mass 
drug administration. The AIM study team had extensive 
preliminary discussions with key stakeholders and 
followed an established process for the introduction of 
new community health initiatives in the Solomon Islands. 
This process included endorsement by the Solomon 
Islands Ministry of Health and Medical Services, and 
engagement with the communities involved. Information 
sheets explaining the study were distributed by trained 
community nurses and were available to study partici­
pants before enrolment.
The study coordinator (LR), who is highly experienced 
in scabies diagnosis, examined the skin of each 
participant for scabies and impetigo at both baseline and 
12 months. One of two local nurses assisted with 
electronic data entry of examination findings using 
Open Data Kit (ODK, Seattle, USA). We used the same 
clinical diagnostic methods for these diseases as used in 
previous studies in Fiji and the Solomon Islands.9,18 
Scabies was defined as pruritic inflammatory papules 
with a typical anatomical distrib ution, such as the webs 
of the fingers, hands, wrists, and ankles, as per integrated 
management of childhood illnesses guidelines.18 Exam­
ination excluded breasts and genitals, unless requested 
by participants and then only in a separate, private 
examination area. Impetigo was defined as papular, 
pustular, or ulcerative lesions surrounded by erythema. 
The definition of crusted scabies we used was as 
previously described.19
All outpatient attendances at government clinics in the 
Solomon Islands are recorded in a standard case register 
(including patient age, sex, reason for attendance) at the 
clinic level. Each month, information collected in these 
registers is required to be transferred electronically via 
the District Health Information System (DHIS2) to the 
Solomon Islands Ministry of Health and Medical Services 
statistics office at the national level. Monthly reporting 
com pleteness is the proportion of clinics that submitted 
a report for that month. Because this proportion varied 
from month to month, we standardised absolute counts 
for Choiseul Province by assuming that those clinics that 
submitted a report were representative of all clinics in 
the province. We obtained data for the 12 months before 
and 12 months after the mass drug administration.
The regimen for trachoma antibiotic mass drug 
administration followed standard WHO guidelines,20 
identical to the regimen used for mass drug admini­
stration for trachoma in the rest of the country. Participants 
were offered a single dose of 20 mg/kg azithromycin, up 
to a maximum of 1 g, using weight­based bands. Children 
weighing less than 12·5 kg received azithromycin oral 
suspension at a dose of 20 mg/kg. Drug administration 
was directly observed for all participants receiving 
azithromycin. Infants younger than 6 months received 
topical 1% tetracycline ointment for administration by a 
parent or guardian to both eyes twice per day for 6 weeks. 
A trained study nurse provided instructions to the parents 
on how to apply tetracycline eye ointment.
For ivermectin­based mass drug administration, 
participants were offered either two doses of oral 
ivermectin 200 μg/kg 7–14 days apart using weight­
based bands, or if ivermectin was contraindicated (such as 
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for pregnant and breastfeeding women and children 
weighing less than 12·5 kg) they were instead offered two 
applications of topical 5% permethrin cream 7–14 days 
apart. Drug administration was directly observed for all 
participants receiving ivermectin. Participants who were 
offered permethrin were given the option to have a trained 
nurse apply the cream in a private room at the clinic or to 
apply it themselves at home. The first dose of ivermectin 
or permethrin was administered at the same time as the 
antibiotic treatment.
Outcomes
The main outcome of the study (a secondary outcome in 
the original AIM trial) was the prevalence of scabies and 
impetigo in the ten randomly selected villages at 
12 months compared with ten different randomly selected 
villages at baseline. We chose a new set of villages at 
12 months to ensure that our estimates of prevalence 
were as generalisable as possible to the whole province. 
Additional analyses were comparison of the total 
number of people who attended outpatient clinics for any 
cause in the 3 months after mass drug administration, 
not including the month of administration, with the 
3 months before mass drug administration. We chose a 
3 month period because of the likelihood (as perceived by 
study investigators) that a clinically meaningful effect of 
mass drug administration at clinic level would persist for 
at least this period of time.21 We excluded analysis of data 
from the month during which mass drug administration 
was being delivered because the intervention was rolled 
out over 4 weeks and might have led to heightened clinic 
activity due to referrals by field teams for incidentally 
found medical issues. In addition to the 3­month 
comparisons, we compared attendance at outpatient 
clinics for any reason the 1 month before and after mass 
drug administration, the 12 months before and after 
mass drug administration (not including the admini­
stration month), and the 3­month period 12 months 
before mass drug administration with the 3­month 
period after mass drug administration.
Furthermore, we also returned to four of the baseline 
villages and compared the prevalence of scabies and 
impetigo at 12 months and baseline in these villages 
using paired analysis.
Statistical analysis
On the basis of 2014 prevalence data from the Solomon 
Islands and SHIFT data,9,13 we expected that the overall 
prevalence of scabies would be approximately 20% at 
baseline, decreasing to less than 5% after mass drug 
administration. We estimated that an overall sample size 
of 1200 individuals would be required at each of the two 
timepoints, assuming 80% participation and accounting 
for a 3% village­level correlation coefficient (assuming 
approximately 50–300 individuals per site at each 
timepoint). This sample size would allow us to estimate 
the prevalence at each timepoint with high precision 
(ie, within 5% or –5% absolute width of the respective 
CIs), and allow us to detect the difference in prevalence 
as significant at the 0·05 level when comparing the 
two timepoints (ie, 20% vs 5%) with 80% power. The 
statistical test of significance for this comparison, to be 
applied at the two­sided 0·05 level, was a χ² test that takes 
into account the sample sizes at both the baseline and 
12­month sampling points and accounts for cluster size.22 
We calculated absolute (difference between baseline and 
month 12) and relative reductions (ratio of month 12 to 
baseline) in prevalence and their 95% CIs on the basis of 
their respective variances using the binomial distri­
bution.23 We analysed the distribution of scabies and 
impetigo by demographic factors and calculated adjusted 
odds ratios (ORs) by fitting a logistic regression model 
adjusting for sex, age group, and village variables. We 
analysed clinic data by age group and by 12 communicable 
disease categories for which data are routinely reported. 
Clinic presentations were adjusted to monthly reporting 
completeness across all clinics in Choiseul Province by 
dividing reported cases by the monthly reporting rate 
(appendix).
We did all analyses using Stata version 14.2. This trial 
was registered with the Australian and New Zealand 
Trials Registry (ACTRN12615001199505).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
In September, 2015, over 4 weeks, 26 188 participants 
were enrolled, 99·3% of the resident population in the 
Figure 1: Study profile
26 188 people living in Choiseul Province
364 declined to participate or were
 absent at time of examination
1625 in 10 villages randomly selected for 12 month
 analysis
1261 enrolled at 12 months
1261 screened for scabies and impetigo
263 declined to participate or were
 absent at time of examination
1662 in 10 randomly selected villages for baseline 
            analysis
1399 enrolled at baseline
1399 screened for scabies and impetigo
375 in 4 villages randomly selected for follow-up 
 at 12 months
See Online for appendix
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Choiseul Province based on the 2009 census (n=26 372).16 
At baseline, of 1662 people living in the ten sentinel 
villages (villages A–J), 1399 (84·2%) consented to 
participate and were examined. 12 months after mass­
drug administration, in September, 2016, of 1625 people 
in the second set of sentinel villages (villages K–T), 
1261 (77·6%) consented to participate and were 
examined (figure 1). The sex and age distributions of 
individuals included in the two samples were similar 
(tables 1 and 2) The locations of each village chosen, 
each designated with a letter from A to T, are shown on 
figure 2. At baseline, 209 (14·9%) of 1399 people in the 
ten baseline sentinel villages were ineligible to receive 
ivermectin, of whom 75 (36%) were children weighing 
less than the required 12·5 kg and 134 (64%) were 
pregnant or breastfeeding women, and so were offered 
permethrin.
In the ten baseline sentinel villages (villages A–J), 
261 people had scabies (18·7%, 95% CI 16·7–20·8; table 3). 
Prevalence was highest in children aged 5–9 years (34·0%, 
95% CI 28·1–40·2; adjusted OR 4·7, 95% CI 3·0–7·2, 
when compared with participants aged 35 years and older; 
appendix). Scabies was more common in girls and women 
than boys and men (adjusted OR 1·3, 95% CI 1·0–1·7; 
appendix). Scabies was observed in all ten baseline sentinel 
villages, with prevalences ranging from 15·1% to 31·5% 
(appendix). 347 people had impetigo (24·8%, 95% CI 
22·6–27·1; table 3), and prevalence was highest among 
children aged 5–9 years (prevalence 46·4%, 95% CI 
40·1–52·8; adjusted OR 7·8, 95% CI 5·1–12·0; appendix).
At 12 months, in the second set of ten sentinel villages 
(villages K–T), 29 people had scabies (2·3%, 95% CI 
Baseline population (n=1399)
Overall
Sex
Male 686 (49·0%)
Female 713 (51·0%)
Age, years
Median 14 (7–34)
<5 231 (16·5%)
5–9 250 (17·9%)
10–14 225 (16·1%)
15–24 175 (12·5%)
25–34 177 (12·6%)
≥35 341 (24·4%)
Village level enrolment
Village A n=209
Participants 178 (12·7%)
Village B n=147
Participants 114 (8·1%)
Village C n=118
Participants 70 (5·0%)
Village D n=174
Participants 157 (11·2%)
Village E n=206
Participants 171 (12·2%)
Village F n=109
Participants 106 (7·6%)
Village G n=219
Participants 162 (11·6%)
Village H n=102
Participants 88 (6·3%)
Village I* n=118
Participants 54 (3·9%)
Village J* n=260
Participants 299 (21·4%)
Data are median (IQR) or n (%) as a proportion of the study population. 
*Residents of villages I and J were seen together because they were all attending a 
social gathering at the time of examination; combined enrolment for villages I 
and J: 353 (93·4%) of 378.
Table 1: Characteristics of participants in ten baseline sentinel villages
Month 12 population (n=1261)
Overall
Sex
Male 570 (45·2%)
Female 691 (54·8%)
Age, years
Median 15 (7–34)
<5 155 (12·3%)
5–9 229 (18·2%)
10–14 209 (16·6%)
15–24 227 (18·0%)
25–34 130 (10·3%)
≥35 311 (24·7%)
Village level enrolment
Village K n=129
Participants 108 (8·6%)
Village L n=186
Participants 95 (7·5%)
Village M n=199
Participants 122 (9·7%)
Village N n=121
Participants 93 (7·4%)
Village O n=165
Participants 156 (12·4%)
Village P n=118
Participants 108 (8·6%)
Village Q n=132
Participants 111 (8·8%)
Village R n=251
Participants 229 (18·1%)
Village S n=109
Participants 70 (5·5%)
Village T n=215
Participants 169 (13·4%)
Data are median (IQR) or n (%) as a proportion of the study population.
Table 2: Characteristics of participants in ten 12-month sentinel villages
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1·6–3·3), corresponding to a relative reduction in 
prevalence of 88% (95% CI 76·5–99·3) from baseline 
(table 3). 81 people had impetigo (prevalence of 6·4%, 
5·2–8·0; relative reduction of 74%, 95% CI 63·4–84·7; 
table 3). Full prevalence data for scabies and impetigo 
by age group and village at 12 months are in the 
appendix.
Among the four randomly selected villages examined 
at both baseline and 12 months, (villages A, B, C, and D) 
the decrease in prevalence of scabies and impetigo 
followed a similar pattern to that observed when com­
paring the two distinct sets of sentinel villages. Overall, 
scabies prevalence decreased from 19·5% (101 of 519) to 
1·3% (five of 375; relative reduction of 93·3%, 95% CI 
74·5–100) and impetigo from 22·4% (116 of 519) to 5·1% 
(19 of 375; relative reduction of 77·2%, 95% CI 58·0–96·0; 
appendix). We observed no cases of crusted scabies 
among participants.
In October to December, 2015, the 3 months after 
mass drug administration, 10 614 people attended 
outpatient clinics in Choiseul Province for any reason 
compared with 16 602 in June to August, 2015, the 
3 months before mass drug administration (table 4), 
corresponding to a decrease of 36·1% (95% CI 
34·7–37·6). We observed a similar decrease when we 
compared attendance in the 1 month periods before 
(August, 2015, n=6269) and after (October, 2015, n=3624) 
mass drug administration (decrease of 42·2%, 95% CI 
41·0–43·4). All­cause out patient attendance decreased 
from 19 789 in October to December, 2014, to 10 614 in 
October to December, 2015, showing a decrease of 
46·4% (95% CI 45·7–47·1). 68 471 people attended 
outpatient clinics during the 12 months before mass 
drug administration (September, 2014, to August, 2015) 
and 59 162 attended in the 12 months after admin­
istration (October, 2015, to September, 2016, a decrease 
of 13·6% (95% CI 13·3–13·9).
The overall decrease in outpatient attendance for 
reported communicable diseases from the 3 months 
before to the 3 months after mass drug administration 
was 40·7% (95% CI 39·6–41·8, table 5). A larger decrease 
was observed for presentations categorised as skin sores, 
boils, and abscesses (50·9%, 95% CI 48·6–53·1) than 
for any other presentation of disease. When comparing 
the 3­month period 12 months before mass drug 
administration (October to December, 2014) with the 
3­month period after (October to December, 2015), we 
observed a large decrease in attendance for communicable 
diseases (55·8%, 95% CI 54·8–56·7; appendix).
Discussion
We found the relative reduction in the prevalence of 
scabies was 88% compared with 94% in SHIFT,9 and the 
decrease in the prevalence of impetigo was substantial 
in both AIM and SHIFT (74% AIM vs 67% SHIFT). 
Hence, the results of the AIM trial reported here show 
that ivermectin­based mass drug administration can 
be scaled to a population of over 25 000 with a similar 
efficacy as in small island­based trial settings and that 
this level of efficacy can be achieved when mass drug 
administration for scabies is integrated with azithromycin 
mass drug administration for trachoma.
Given the absence of any known biological effect 
of ivermectin on bacterial organisms that cause skin 
infections, the substantial decrease in the prevalence of 
impetigo observed in AIM and SHIFT strongly support 
the hypothesis that scabies is an important causal factor 
for impetigo. The decrease in impetigo burden here 
Baseline 12 months Absolute reduction 
in prevalence
Relative reduction 
in prevalence
Scabies
n/N 261/1399 29/1261 ·· ··
Prevalence 18·7% (16·7–20·8) 2·3% (1·6–3·3) 16·4% (14·2–18·6) 88% (76·5–99·3)
Impetigo
n/N 347/1399 81/1261 ·· ··
Prevalence 24·8% (22·6–27·1) 6·4% (5·2–8·0) 18·4% (15·7–21·0) 74% (63·4–84·7)
Data are n/N and prevalence, with 95% CIs in parentheses.
Table 3: Prevalence of scabies and impetigo at baseline and 12 months
June–August, 2015 October–December, 2015 Reduction in presentations
Age group, years
0–<1 765 638 128 (16·7%)
1–4 2618 1973 645 (24·6%)
5–14 2733 1516 1217 (44·5%)
15–49 7470 4429 3041 (40·7%)
≥50 3016 2058 958 (31·8%)
Total 16 602 10 614 5989 (36·1%)
Data are n and n (% reduction).
Table 4: Outpatient all-cause clinic attendance in the 3 months before and after the intervention
Study villages
Baseline survey
Follow-up survey
Provincial capitalTaro
L
S
P
D
A
B
C
H
F
N
J
I
E R
O
Q
G
T
M
K
Figure 2: Villages selected for baseline and follow-up surveys in Choiseul Province, Solomon Islands
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exceeded estimates of the population­attributable risk of 
impetigo due to scabies in previous studies in the Pacific 
Islands.13,24 The slightly greater decrease in prevalence 
of impetigo in AIM than in SHIFT, combined with 
the known activity of azithromycin against both 
Staphylococcus aureus and Streptococcus pyogenes,25 raises 
the possibility that azithromycin mass drug admin­
istration might have had an additional effect on the 
prevalence of impetigo beyond that of ivermectin­based 
mass drug administration alone. However, a community­
based trial26 in the Solomon Islands in 2016–17 comparing 
ivermectin mass drug administration with ivermectin 
plus azithromycin mass drug administration found no 
difference in the decrease in prevalence of impetigo 
between the two groups at 12 months after the inter­
vention (relative reduction 75% vs 73%; p=0·49).26
The AIM trial has shown that integration of mass 
drug administration for control of scabies and trachoma 
is feasible. However, other than a previous study in 
Zanzibar,12 few assessments of the effect of mass drug 
administration containing ivermectin for lymphatic 
filariasis and onchocerciasis on other neglected tropical 
diseases exist.27 Formal assessments of the effect of these 
programmes on scabies and other neglected tropical 
diseases, such as strongyloidiasis, would be of value in 
fully characterising the benefits of ivermectin mass drug 
administration, and the roll­out of triple therapy for 
control of lymphatic filariasis (ivermectin, diethylcarbam­
azine, and albendazole) provides a crucial opportunity to 
assess the effect of this regimen on scabies.28 The 
importance of making permethrin available for children 
and others who are contraindicated for ivermectin, as 
done in this study, needs to be assessed in these other 
mass drug administration programmes.
We observed a substantial effect of ivermectin and 
azithromycin mass drug administration on attendance at 
outpatient clinics, including attendance for skin sores, 
boils, and skin abscesses, yaws, acute respiratory 
infections, and diarrhoeal disease. These broader health 
benefits have been documented previously after mass 
drug administration of azithromycin for trachoma,29–31 
including as documented in randomised trials that have 
found a decrease in overall mortality in young children.29,32 
Although the effect on acute respiratory infections and 
diarrhoeal disease observed in AIM is probably associated 
with azithromycin alone, the effect on attendance at 
outpatient clinics for bacterial skin infection might have 
been driven by both ivermectin and azithromycin.
To inform development of public health policies for 
effective scabies control, several outstanding research 
questions associated with implem entation of mass 
drug administration for scabies exist, in addition to 
those associated with scalability and integration. These 
questions include the effect of mass drug administration 
on the complications of scabies and impetigo, including 
severe skin and soft tissue infections, sepsis due 
to S aureus and S pyogenes, glomerulonephritis, and 
rheumatic fever. Monitoring of resistance in bacteria 
after azithromycin mass drug administration and in 
parasites after ivermectin mass drug administration will 
be necessary to mitigate any unintended consequence 
of large­scale control pro grammes.33 Although small 
targeted studies might be necessary to answer questions 
about optimal ivermectin dosing, implementation 
research alongside large­scale roll­out of mass drug 
administration could be of use to assess the effect of 
mass drug administration on complications of scabies 
and impetigo, cost­effectiveness, community accept­
ability, staff training, and distribution logistics.
Our study had several limitations. Our study was 
non­randomised, employing a pragmatic before­and­after 
design appropriate for assessment of the effect of 
the intervention when delivered in such a large­scale 
(province­wide) setting, so we cannot say with certainty 
that factors other than the intervention did not influence 
our findings. Nevertheless, we are unaware of any other 
changes over the study period that could have accounted 
for a decrease in the prevalence of scabies and impetigo of 
the observed magnitude. With demographic characteristics 
of the population samples at the two timepoints being 
very similar, the difference in non­participation at 
12 months (22·4%) versus baseline (15·8%) is unlikely 
to have influenced the findings. We chose ten distinct 
villages at baseline and 12 months for assessment to 
eliminate bias that might have been introduced through 
the presence of the study team. The additional paired 
analysis of the four villages seen at both baseline and 
12 months supports our overall efficacy findings.
In the AIM trial, we offered two doses of ivermectin as 
part of mass drug administration, whereas in SHIFT9 a 
second dose was only provided to those who had clinical 
scabies because the SHIFT study team was able to 
screen all individuals within the small study population 
June–August, 
2015
October–December, 
2015
Reduction in 
presentations (%)
Presentation
Acute respiratory infection 4185 2673 1512 (36%)
Skin sores, boils, and abscesses 1931 949 982 (51%)
Acute ear infection 578 428 150 (26%)
Watery diarrhoea 352 219 133 (38%)
Red eye 239 161 78 (33%)
Chronic ear infection 130 59 71 (55%)
Yaws 114 15 99 (87%)
Fungal skin infection 107 54 53 (50%)
Bloody diarrhoea 58 14 44 (76%)
Scabies 26 8 18 (69%)
Neonatal bacterial infection 4 0 4 (100%)
Total 7723 4578 3144 (41%)
Data are n and n (% reduction).
Table 5: Outpatient clinic attendance for communicable diseases syndromes in the 3 months before and 
after mass drug administration
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(n=716). Although some experts suggest3 that the use of 
environmental measures might play a role in decreasing 
reinfestation, we found that mass drug administration 
alone has high efficacy in decreasing community 
prevalence of scabies and impetigo.3 Because a second dose 
of ivermectin adds complexity and cost to a pro gramme of 
mass drug administration, studies are on going to 
determine whether the same benefit can be achieved 
with a single dose of ivermectin for scabies control in 
highly endemic settings (ACTRN12618001086257 and 
ACTRN12617000738325). Finally, the data available to us 
for outpatient presentations were generated through 
routine reporting, which might have led to under­reporting 
of specific diseases, but the conditions for reporting were 
the same in the periods before and after the intervention. 
Front­line clinicians and health­informatics staff were not 
made aware in advance that the number of people attending 
clinics was being collected as part of this research.
In the AIM trial, ivermectin plus antibiotic mass 
drug administration was highly effective at decreasing 
scabies and impetigo prevalence at 12 months after the 
intervention in a population of over 25 000 people in a 
province in the Solomon Islands. Other substantial 
short­term health benefits were observed, with notable 
decreases in all­cause outpatient clinic attendance and 
presentations for multiple communicable diseases. 
Scabies was designated by WHO as a neglected tropical 
disease in April, 2017, and countries are now considering 
how they will seek to control the disease within a public 
health framework. The efficacy data presented here 
support large­scale implementation of ivermectin­based 
mass drug administration for control of scabies in areas 
where scabies is identified as a public health priority. 
Operational research should be undertaken alongside 
roll­out of such interventions, to assess durability in the 
decrease of scabies and impetigo and the effect of mass 
drug administration on the complications of scabies and 
impetigo, cost­effectiveness, and acceptability.
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